Diagnostic of Chronic Thrombocytopenia

NCT04071496 | Completed

• 1 other identifier: CHUBX 2008/06
• Study Type: observational
• Target: 158
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objective of this study is to provide simple and relevant clinical and biological elements to distinguish a possible Congenital Thrombocytopenia from a Chronic Idiopathic Thrombocytopenic Purpura .

Conditions

Congenital Thrombocytopenia; Chronic Idiopathic Thrombocytopenic Purpura

Outcome Measures

Primary Outcomes (2)

• Modelization of congenital thrombocytopenia test

  Taking into account the clinical and biological data of patients (flow cytometry and electron microscopy), validation using resampling methods (bootstrap, jacknife, cross validation ...)

  AT the screening

• Modelization of chronic idiopathic thrombocytopenic purpura test

  Taking into account the clinical and biological data of patients (flow cytometry and electron microscopy), validation using resampling methods (bootstrap, jacknife, cross validation ...)

  AT the screening

Interventions

Blood samples OTHER

1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Congenital Thrombocytopenia Patients and Chronic Idiopathic Thrombocytopenic Purpura Patients

You may qualify if:

• All patients with chronic thrombocytopenia (\> 6 months) between 10 and 150 G / L, regardless of age or gender,
• Subjects with a definite Chronic Idiopathic thrombocytopenic purpuras, - Subjects with a certain degree of certainty, sometimes pre-identified and already known at the level of the C reactive protein,
• Subjects with chronic thrombocytopenia of undetermined origin, not definitively entering one of the 2 groups mentioned above.

You may not qualify if:

• Thrombocytopenia less than 6 months old;
• Patients with thrombocytopenia related to a viral or chronic infectious pathology (HIV infections or hepatitis C virus, bacterial infections with Helicobacter pillory, for example), an autoimmune disease, in particular systemic lupus and / or antiphospholipid syndrome, a bleeding disorder such as a Intra-vascular Disseminated coagulation, thrombotic microangiopathy, hypersplenism, a responsible medication intake, myelodysplastic syndrome, a pregnancy in progress.
• Patients should not be treated with Immunoglobulin IV, rituximab or anti-CD20 less than 30 days before the date of collection.

Sponsors & Collaborators

• University Hospital, Bordeaux: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Paquita NURDEN, Dr

  University Hospital, Bordeaux

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 23, 2019
• First Posted: August 28, 2019
• Study Start: November 25, 2009
• Primary Completion: March 12, 2012
• Study Completion: March 12, 2012
• Last Updated: August 28, 2019

Record last verified: 2019-08

Data Sharing

• IPD Sharing: Will not share